Full Press Release Details
Broadly Supports Oragenics' Pre-IND Development Program for its SARS-CoV-2 Vaccine
Plan to File IND Application by the End of 1Q21, Begin Phase 1 Study in Early 2Q21
(October 6, 2020) - Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") announced
receipt of feedback to its Type B Pre-IND Meeting Request from the U.S. Food and Drug Administration ("FDA") that
it is in broad agreement with the Company's planned approach to clinical development of its SARS-CoV-2 vaccine, Terra CoV-2.
As a result, the Company believes its timelines for both filing an Investigational New Drug ("IND") application and
the commencement of the Phase 1 study will proceed on schedule. Oragenics expects to file the IND by the end of the first quarter
of 2021 and commence patient enrollment in the Phase 1 clinical study early in the second quarter of 2021.
are very pleased with the FDA's response to our Type B Pre-IND meeting request as it permits us to maintain an aggressive
development timeline for our Terra CoV-2 vaccine," said Alan Joslyn, Ph.D., President and Chief Executive Officer of Oragenics.
"Important points that are supportive of our planned approach received favorable feedback."
Joslyn added, "The FDA's response is an important step as we work to provide a vaccine against SARS-CoV-2 that is
focused on the stabilized prefusion spike protein, with a potential profile that may include lifetime immunity to COVID-19, and
storage and distribution at refrigerated temperatures. We believe the commercial opportunity for Terra CoV-2 is robust, and that
our vaccine will find its place in the global fight against this deadly virus."
FDA has requested additional preclinical animal data for inclusion in the IND filing and plans to provide final comments upon
reviewing that data and the Phase 1 trial protocol. Oragenics believes that generating the additional data will not impede the
overall development timeline.
March 2020, Oragenics acquired a non-exclusive license from the National Institutes of Health ("NIH") for its stabilized
prefusion Terra CoV-2 spike protein. Oragenics recently announced that its spike protein had been successfully inserted into Chinese
Hamster Ovary ("CHO") cells and "mini-pool" production and analytical development are underway. CHO cells
are used to produce a number of FDA-approved recombinant proteins.
Inc. is focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic and the further
development of effective treatments for novel antibiotics against infectious disease. The Company is dedicated to the development
and commercialization of a vaccine candidate providing specific immunity from novel coronavirus. The Terra CoV-2 immunization
leverages coronavirus spike protein research conducted by the National Institute of Health. In addition, Oragenics has an exclusive
worldwide channel collaboration with ILH Holdings, Inc. (n/k/a Eleszto Genetika, Inc.), relating to the development of novel lantibiotics.
more information about Oragenics, please visit www.oragenics.com.
the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect management's
current views with respect to future events and performance. These forward-looking statements are based on management's
beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate,"
"intend," "estimate," "project" and similar expressions that do not relate solely to historical
matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they
are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from
those expressed in any such forward-looking statements. These factors include, but are not limited to, the following: the Company's
ability to advance the development of TerraCoV-2 under the timelines and in accord with the milestones it projects; the Company's
ability to obtain funding, non-dilutive or otherwise, for the development of Noachis Terra's TerraCoV-2 vaccine, whether
through its own cash on hand, or another alternative source; the regulatory application process, research and development stages,
and future clinical data and analysis relating to TerraCoV-2, including any meetings, decisions by regulatory authorities, such
as the FDA and investigational review boards, whether favorable or unfavorable; the Company's ability to obtain, maintain
and enforce necessary patent and other intellectual property protection; the nature of competition and development relating to
COVID-19 immunization and therapeutic treatments; other potential adverse impacts due to the global COVID-19 pandemic, such as
delays in regulatory review, interruptions to manufacturers and supply chains, adverse impacts on healthcare systems and disruption
of the global economy; and general economic and market conditions risks, as well as other uncertainties described in our filings
with the U.S. Securities and Exchange Commission. Oragenics assumes no responsibility to update any forward-looking statements
contained in this press release or with respect to the matters described herein.